APRE

Aprea Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website aprea.com
Employees(FY) 9
ISIN US03836J2015

Performance

-4.18%

1W

-9.91%

1M

-9.57%

3M

+40.53%

6M

+12.13%

YTD

+37.24%

1Y

Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of APRE 2024-05-10

Overview:

In analyzing the technical indicators for APRE over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...

See more ...

Recent News & Updates

2024-05-14 01:53
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-13 20:30
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-05-13 04:01
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference(Globenewswire)
2024-05-01 21:15
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-04-10 00:00
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024(Globenewswire)
2024-03-26 01:53
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-03-25 19:45
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update(Globenewswire)
2024-03-10 20:30
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million(Globenewswire)
2024-03-10 20:29
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers(Globenewswire)
2024-03-05 03:45
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024(Globenewswire)
2024-02-05 19:01
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor(Globenewswire)
2024-01-29 19:00
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024(Globenewswire)
2024-01-04 03:05
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024(Globenewswire)
2023-11-09 03:05
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update(Globenewswire)
2023-10-23 20:00
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways(Globenewswire)
2023-10-15 20:30
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio(Globenewswire)
2023-09-18 20:00
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics(Yahoo Finance)
2023-09-10 20:00
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors(Yahoo Finance)
2023-09-06 04:05
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-23 19:30
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman(Yahoo Finance)
2023-08-09 19:30
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations(Yahoo Finance)
2023-06-13 20:00
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference(Yahoo Finance)
2023-05-29 20:30
Aprea Therapeutics to Present at BIO International Convention(Yahoo Finance)
2023-05-15 04:05
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations(Yahoo Finance)
2023-05-07 20:00
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors(Yahoo Finance)
2023-04-23 21:55
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now(Yahoo Finance)
2023-04-04 00:00
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy(Yahoo Finance)
2023-03-30 04:05
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations(Yahoo Finance)
2023-03-15 20:00
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting(Yahoo Finance)
2023-03-06 19:00
Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference(Yahoo Finance)

Page 1 of 4

previousnext